VIR
vs
S&P 500
VIR
S&P 500
Over the past 12 months, VIR has underperformed S&P 500, delivering a return of -12% compared to the S&P 500's +12% growth.
Stocks Performance
VIR vs S&P 500
Performance Gap
VIR vs S&P 500
Performance By Year
VIR vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Vir Biotechnology Inc
Glance View
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 444 full-time employees. The company went IPO on 2019-10-11. The company has assembled four technology platforms focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA), through internal development, collaborations, and acquisitions. The firm's pipeline consists of sotrovimab and other product candidates targeting COVID-19, hepatitis B virus (HBV), influenza A virus, and human immunodeficiency virus (HIV). Its product candidates include Sotrovimab and VIR-7832, VIR-2218, VIR-3434, VIR-2482, VIR-1111. The company is engaged in developing differentiated monoclonal antibodies (mAbs) as well as vaccines and small molecules that focuses is on treating and preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VIR-2218 and VIR-3434, are for the treatment of HBV. VIR-2482 is an investigational IM administered influenza A-neutralizing mAb.
